IG/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas

American Journal of Surgical Pathology

Volumn 34, Issue 11, 2010, Pages 1686-1694

  Valera, Alexandra ^a   Balagué, Olga ^a   Colomo, Luis ^a   Martínez, Antonio ^a   Delabie, Jan ^b   Taddesse Heath, Lekidelu ^c   Jaffe, Elaine S ^d   Campo, Elías ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF OSLO   (Norway)

^c HOWARD UNIVERSITY HOSPITAL   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

FISH; MYC; plasmablastic lymphoma

Indexed keywords

MYC PROTEIN; MYC PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CHILD; CHROMOSOME ANALYSIS; EPSTEIN BARR VIRUS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; GENE TRANSLOCATION; GENETICS; HUMAN; IMMUNOGLOBULIN GENE; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; IMMUNOPHENOTYPING; ISOLATION AND PURIFICATION; LARGE CELL LYMPHOMA; MALE; MIDDLE AGED; MORTALITY; PLASMA CELL; PROGNOSIS; TIME; VIROLOGY;

ADULT; AGED; AGED, 80 AND OVER; CHILD; CYTOGENETIC ANALYSIS; FEMALE; GENE REARRANGEMENT; GENES, IMMUNOGLOBULIN; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PLASMA CELLS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MYC; TIME FACTORS; TRANSLOCATION, GENETIC;

EID: 78049526679     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e3181f3e29f     Document Type: Article

References (42)

1. Ascoli V, Mastroianni CM, Galati V, et al. Primary effusion lymphoma containing human herpesvirus 8 DNA in two AIDS patients with Kaposi's sarcoma. Haematologica. 1998;83:8-12.
2. Avet-Loiseau H, Gerson F, Magrangeas F, et al. Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors. Blood. 2001;98:3082-3086.
3. Balague O, Martinez A, Colomo L, et al. Epstein-Barr virus negative clonal plasma cell proliferations and lymphomas in peripheral T-cell lymphomas: a phenomenon with distinctive clinicopathologic features. Am J Surg Pathol. 2007;31:1310-1322.
4. Bea S, Campo E. Secondary genomic alterations in non-Hodgkin's lymphomas: tumor-specific profiles with impact on clinical behavior. Haematologica. 2008;93:641-645.
5. Bea S, Zettl A, Wright G, et al. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood. 2005;106:3183-3190.
6. Bink K, Haralambieva E, Kremer M, et al. Primary extramedullary plasmacytoma: similarities with and differences from multiple myeloma revealed by interphase cytogenetics. Haematologica. 2008; 93:623-626.
7. Bogusz AM, Seegmiller AC, Garcia R, et al. Plasmablastic lymphomas with MYC/IgH rearrangement: report of three cases and review of the literature. Am J Clin Pathol. 2009;132:597-605.
8. Boulanger E, Agbalika F, Maarek O, et al. A clinical, molecular and cytogenetic study of 12 cases of human herpesvirus 8 associated primary effusion lymphoma in HIV-infected patients. Hematol J. 2001;2:172-179. (Pubitemid 32633668)
9. Bubman D, Guasparri I, Cesarman E. Deregulation of c-Myc in primary effusion lymphoma by Kaposi's sarcoma herpesvirus latency-associated nuclear antigen. Oncogene. 2007;26:4979-4986.
10. Capello D, Scandurra M, Poretti G, et al. Genome wide DNA-profiling of HIV-related B-cell lymphomas. Br J Haematol. 2010;148 :245-255.
11. Castillo J, Pantanowitz L, Dezube BJ. HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases. Am J Hematol. 2008;83:804-809.
12. Chadburn A, Hyjek E, Mathew S, et al. KSHV-positive solid lymphomas represent an extra-cavitary variant of primary effusion lymphoma. Am J Surg Pathol. 2004;28:1401-1416.
13. Chuah KL, Ng SB, Poon L, et al. Plasmablastic lymphoma affecting the lung and bone marrow with CD10 expression and t(8;14)(q24;q32) translocation. Int J Surg Pathol. 2009;17:163-166.
14. Colomo L, Loong F, Rives S, et al. Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities. Am J Surg Pathol. 2004;28:736-747.
15. Dawson MA, Schwarer AP, McLean C, et al. AIDS-related plasmablastic lymphoma of the oral cavity associated with an IGH/MYC translocation-treatment with autologous stem-cell transplantation in a patient with severe haemophilia-A. Haemato-logica. 2007;92:e11-e12.
16. Delecluse HJ, Anagnostopoulos I, Dallenbach F, et al. Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood. 1997;89:1413-1420.
17. Dong HY, Scadden DT, de Leval L, et al. Plasmablastic lymphoma in HIV-positive patients: an aggressive Epstein-Barr virus-associated extramedullary plasmacytic neoplasm. Am J Surg Pathol. 2005; 29:1633-1641.
18. Fujisawa S, Tanioka F, Matsuoka T, et al. CD5+ diffuse large B-cell lymphoma with c-myc/IgH rearrangement presenting as primary effusion lymphoma. Int J Hematol. 2005;81:315-318.
19. Gabrea A, Leif BP, Michael KW. Distinguishing primary and secondary translocations in multiple myeloma. DNA Repair (Amst). 2006;5:1225-1233.
20. Gabrea A, Martelli ML, Qi Y, et al. Secondary genomic rearrangements involving immunoglobulin or MYC loci show similar prevalences in hyperdiploid and nonhyperdiploid myeloma tumors. Genes Chromosomes Cancer. 2008;47:573-590.
21. Gaidano G, Cerri M, Capello D, et al. Molecular histogenesis of plasmablastic lymphoma of the oral cavity. Br J Haematol. 2002; 119:622-628.
22. Garcia JF, Roncador G, Garcia JF, et al. PRDM1/BLIMP-1 expression in multiple B and T-cell lymphoma. Haematologica. 2006;91:467-474.
23. Hummel M, Bentink S, Berger H, et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med. 2006;354:2419-2430.
24. Ichinohasama R, Miura I, Kobayashi N, et al. Herpes virus type 8-negative primary effusion lymphoma associated with PAX-5 gene rearrangement and hepatitis C virus: a case report and review of the literature. Am J Surg Pathol. 1998;22:1528-1537.
25. Johnson NA, Savage KJ, Ludkovski O, et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood. 2009;114:2273-2279.
26. Kelly GL, Milner AE, Baldwin GS, et al. Three restricted forms of Epstein-Barr virus latency counteracting apoptosis in c-myc-expres-sing Burkitt lymphoma cells. Proc Natl Acad Sci \USA. 2006; 103:14935-14940.
27. Klapproth K, Wirth T. Advances in the understanding of MYC-induced lymphomagenesis. Br J Haematol. 2010;149:484-497.
28. Lin Y, Wong K, Calame K. Repression of c-myc transcription by Blimp-1, an inducer of terminal B cell differentiation. Science. 1997; 276:596-599.
29. Mohamed AN, Bentley G, Bonnett ML, et al. Chromosome aberrations in a series of 120 multiple myeloma cases with abnormal karyotypes. Am J Hematol. 2007;82:1080-1087.
30. Montes-Moreno S, Gonzalez-Medina AR, Rodriguez Pinilla SM, et al. Aggressive large B cell lymphoma with plasma cell differentiation: immunohistochemical characterization of plasmablastic lymphoma and diffuse large B cell lymphoma with partial plasmablastic phenotype. Haematologica. 2010;95:1342-1349.
31. Niitsu N, Okamoto M, Miura I, et al. Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations. Leukemia. 2009;23:777-783.
32. Salaverria I, Zettl A, Bea S, et al. Chromosomal alterations detected by comparative genomic hybridization in subgroups of gene expression-defined Burkitt's lymphoma. Haematologica. 2008;93: 1327-1334.
33. Sawyer JR, Lukacs JL, Munshi N, et al. Identification of new nonrandom translocations in multiple myeloma with multicolor spectral karyotyping. Blood. 1998;92:4269-4278.
34. Snuderl M, Kolman OK, Chen YB, et al. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol. 2010;34:327-340.
35. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC; 2008.
36. Taddesse-Heath L, Meloni-Ehrig A, Scheerle J, et al. Plasmablastic lymphoma with MYC translocation: evidence for a common pathway in the generation of plasmablastic features. Mod Pathol. 2010. doi:10.1038/modpathol.2010.72.
37. Tchinda J, Volpert S, Kropff M, et al. Frequent gains of the short arm of chromosome 9 in multiple myeloma with normal G-banded karyotype detected by comparative genomic hybridization. Am J Clin Pathol. 2004;122:875-882.
38. Tomita N, Tokunaka M, Nakamura N, et al. Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations. Haematologica. 2009;94:935-943.
39. Van RA, Mason D, Jones M, et al. Translocation detection in lymphoma diagnosis by split-signal FISH: a standardised approach. J Hematop. 2008;1:119-126.
40. Vega F, Chang CC, Medeiros LJ, et al. Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immuno-phenotypic profiles. Mod Pathol. 2005;18:806-815.
41. Ventura RA, Martin-Subero JI, Jones M, et al. FISH analysis for the detection of lymphoma-associated chromosomal abnormalities in routine paraffin-embedded tissue. J Mol Diagn. 2006;8: 141-151.
42. Yotsumoto M, Ichikawa N, Ueno M, et al. CD20-negative CD138-positive leukemic large cell lymphoma with plasmablastic differentiation with an IgH/MYC translocation in an HIV-positive patient. Intern Med. 2009;48:559-562.